Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada; Department of Psychiatry and Addiction, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada; Department of Psychiatry and Addiction, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada; Department of Psychiatry, Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada.
Psychiatry Res. 2023 Aug;326:115276. doi: 10.1016/j.psychres.2023.115276. Epub 2023 May 30.
Innovative technology-based solutions have the potential to improve access to clinically proven interventions for cannabis use disorder (CUD) in individuals with first episode psychosis (FEP). High patient engagement with app-based interventions is critical for achieving optimal outcomes. 104 individuals 18 to 35 years old with FEP and CUD from three Canadian provinces completed an electronic survey to evaluate preferences for online psychological intervention intensity, participation autonomy, feedback related to cannabis use, and technology platforms and app functionalities. The development of the questionnaire was informed by a qualitative study that included patients and clinicians. We used Best-Worst Scaling (BWS) and item ranking methodologies to measure preferences. Conditional logistic regression models for BWS data revealed high preferences for moderate intervention intensity (e.g., modules with a length of 15 min) and treatment autonomy that included preferences for using technology-based interventions and receiving feedback related to cannabis use once a week. Luce regression models for rank items revealed high preferences for smartphone-based apps, video intervention components, and having access to synchronous communications with clinicians and gamification elements. Results informed the development of iCanChange (iCC), a smartphone-based intervention for the treatment of CUD in individuals with FEP that is undergoing clinical testing.
基于创新技术的解决方案有可能改善首次精神病发作（FEP）患者的大麻使用障碍（CUD）的临床验证干预措施的可及性。患者高度参与基于应用程序的干预措施对于实现最佳效果至关重要。来自加拿大三个省份的 104 名年龄在 18 至 35 岁之间的 FEP 和 CUD 患者完成了一项电子调查，以评估对在线心理干预强度、参与自主性、与大麻使用相关的反馈以及技术平台和应用程序功能的偏好。该问卷的制定是通过包括患者和临床医生的定性研究来指导的。我们使用最佳最差评分（BWS）和项目排名方法来衡量偏好。BWS 数据的条件逻辑回归模型显示出对中等干预强度（例如，模块长度为 15 分钟）和治疗自主性的高度偏好，其中包括使用基于技术的干预措施和每周接收一次与大麻使用相关的反馈的偏好。排名项目的 Luce 回归模型显示出对基于智能手机的应用程序、视频干预组件以及与临床医生进行同步通信和游戏化元素的高度偏好。结果为 iCanChange（iCC）的开发提供了信息，iCC 是一种针对 FEP 患者 CUD 的基于智能手机的干预措施，正在进行临床测试。
